» Articles » PMID: 28545044

Differentiation of Spontaneously Contracting Cardiomyocytes from Non-virally Reprogrammed Human Amniotic Fluid Stem Cells

Overview
Journal PLoS One
Date 2017 May 26
PMID 28545044
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Congenital heart defects are the most common birth defect. The limiting factor in tissue engineering repair strategies is an autologous source of functional cardiomyocytes. Amniotic fluid contains an ideal cell source for prenatal harvest and use in correction of congenital heart defects. This study aims to investigate the potential of amniotic fluid-derived stem cells (AFSC) to undergo non-viral reprogramming into induced pluripotent stem cells (iPSC) followed by growth-factor-free differentiation into functional cardiomyocytes. AFSC from human second trimester amniotic fluid were transfected by non-viral vesicle fusion with modified mRNA of OCT4, KLF4, SOX2, LIN28, cMYC and nuclear GFP over 18 days, then differentiated using inhibitors of GSK3 followed 48 hours later by inhibition of WNT. AFSC-derived iPSC had high expression of OCT4, NANOG, TRA-1-60, and TRA-1-81 after 18 days of mRNA transfection and formed teratomas containing mesodermal, ectodermal, and endodermal germ layers in immunodeficient mice. By Day 30 of cardiomyocyte differentiation, cells contracted spontaneously, expressed connexin 43 and β-myosin heavy chain organized in sarcomeric banding patterns, expressed cardiac troponin T and β-myosin heavy chain, showed upregulation of NKX2.5, ISL-1 and cardiac troponin T with downregulation of POU5F1, and displayed calcium and voltage transients similar to those in developing cardiomyocytes. These results demonstrate that cells from human amniotic fluid can be differentiated through a pluripotent state into functional cardiomyocytes.

Citing Articles

Cell Reprogramming and Differentiation Utilizing Messenger RNA for Regenerative Medicine.

Inagaki M J Dev Biol. 2024; 12(1).

PMID: 38535481 PMC: 10971469. DOI: 10.3390/jdb12010001.


RNA-Based Strategies for Cell Reprogramming toward Pluripotency.

Bailly A, Milhavet O, Lemaitre J Pharmaceutics. 2022; 14(2).

PMID: 35214051 PMC: 8876983. DOI: 10.3390/pharmaceutics14020317.


Application of Modified mRNA in Somatic Reprogramming to Pluripotency and Directed Conversion of Cell Fate.

Wang A Int J Mol Sci. 2021; 22(15).

PMID: 34360910 PMC: 8348611. DOI: 10.3390/ijms22158148.


Hypoxia-induced amniotic fluid stem cell secretome augments cardiomyocyte proliferation and enhances cardioprotective effects under hypoxic-ischemic conditions.

Kukumberg M, Phermthai T, Wichitwiengrat S, Wang X, Arjunan S, Chong S Sci Rep. 2021; 11(1):163.

PMID: 33420256 PMC: 7794288. DOI: 10.1038/s41598-020-80326-w.


Stirred Suspension Bioreactor Culture of Porcine Induced Pluripotent Stem Cells.

Burrell K, Dardari R, Goldsmith T, Toms D, Villagomez D, King W Stem Cells Dev. 2019; 28(18):1264-1275.

PMID: 31264514 PMC: 6751395. DOI: 10.1089/scd.2019.0111.


References
1.
Qin M, Chen R, Li H, Liang H, Xue Q, Li F . Direct Reprogramming of Human Amniotic Fluid Stem Cells by OCT4 and Application in Repairing of Cerebral Ischemia Damage. Int J Biol Sci. 2016; 12(5):558-68. PMC: 4807416. DOI: 10.7150/ijbs.11051. View

2.
Jiang G, Herron T, Di Bernardo J, Walker K, OShea K, Kunisaki S . Human Cardiomyocytes Prior to Birth by Integration-Free Reprogramming of Amniotic Fluid Cells. Stem Cells Transl Med. 2016; 5(12):1595-1606. PMC: 5189652. DOI: 10.5966/sctm.2016-0016. View

3.
Caspi O, Lesman A, Basevitch Y, Gepstein A, Arbel G, Habib I . Tissue engineering of vascularized cardiac muscle from human embryonic stem cells. Circ Res. 2007; 100(2):263-72. DOI: 10.1161/01.RES.0000257776.05673.ff. View

4.
Drukker M, Katchman H, Katz G, Even-Tov Friedman S, Shezen E, Hornstein E . Human embryonic stem cells and their differentiated derivatives are less susceptible to immune rejection than adult cells. Stem Cells. 2005; 24(2):221-9. DOI: 10.1634/stemcells.2005-0188. View

5.
Okano H, Nakamura M, Yoshida K, Okada Y, Tsuji O, Nori S . Steps toward safe cell therapy using induced pluripotent stem cells. Circ Res. 2013; 112(3):523-33. DOI: 10.1161/CIRCRESAHA.111.256149. View